Collegium Pharmaceutical to Present Real-World Data on ADHD Drug Jornay PM at 2025 National Conference

Summary

Collegium Pharmaceutical, Inc. announced that it will present two poster sessions on real-world data for its ADHD treatment drug Jornay PM at the National Association of Pediatric Nurse Practitioners 2025 National Conference in Chicago. The presentations will highlight patient persistence and compliance, as well as demographic and medication data from a large U.S. claims database. The conference is from March 10-13, 2025, and emphasizes Collegium’s commitment to improving the lives of ADHD patients through differentiated medication.

Impact Analysis

This event is classified at the company level, as it pertains directly to Collegium Pharmaceutical’s strategic move to showcase its ADHD medication Jornay PM. The presentation of real-world data at a national conference could enhance Collegium’s reputation within the healthcare community and potentially influence prescriber behavior. First-order effects include increased visibility and credibility among healthcare professionals, which may boost prescription rates and drive revenue growth. Second-order effects could involve increased investor interest due to the potential for expanded market share, especially if the data demonstrates significant advantages over competitors’ offerings. Investment opportunities may arise in the form of increased stock valuation if the presentations lead to favorable reception and subsequent market performance.Market Beat+ 2Market Beat